Abstract
Pd/C-Cu mediated alternative and one-pot method has been developed for the synthesis of (Z)-3- methyleneisoindolin-1-ones as potential inhibitors of PDE4. The methodology involved coupling-cyclization of obromobenzamides with a range of terminal alkynes in a single pot to afford the target compounds in acceptable yields. Some of these compounds showed encouraging inhibition of PDE4 when tested in vitro that was supported by in silico docking studies.
Keywords: Alkynes, Pd/C, coupling, 3-methyleneisoindolin-1-ones.
Letters in Drug Design & Discovery
Title:Pd/C-mediated Synthesis of 3-methyleneisoindolin-1-ones: Biological and Theoretical Study of their PDE4 Inhibition
Volume: 11 Issue: 10
Author(s): Suryadevara Vijayavardhini, Dandela Rambabu, Vegendla Anuradha, Ravikumar Kapavarapu, Mandava Venkata Basaveswara Rao and Manojit Pal
Affiliation:
Keywords: Alkynes, Pd/C, coupling, 3-methyleneisoindolin-1-ones.
Abstract: Pd/C-Cu mediated alternative and one-pot method has been developed for the synthesis of (Z)-3- methyleneisoindolin-1-ones as potential inhibitors of PDE4. The methodology involved coupling-cyclization of obromobenzamides with a range of terminal alkynes in a single pot to afford the target compounds in acceptable yields. Some of these compounds showed encouraging inhibition of PDE4 when tested in vitro that was supported by in silico docking studies.
Export Options
About this article
Cite this article as:
Vijayavardhini Suryadevara, Rambabu Dandela, Anuradha Vegendla, Kapavarapu Ravikumar, Basaveswara Rao Venkata Mandava and Pal Manojit, Pd/C-mediated Synthesis of 3-methyleneisoindolin-1-ones: Biological and Theoretical Study of their PDE4 Inhibition, Letters in Drug Design & Discovery 2014; 11 (10) . https://dx.doi.org/10.2174/1570180811666140717190618
DOI https://dx.doi.org/10.2174/1570180811666140717190618 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Modulation and New Mediators in Inflammation Executive (Guest Editor: Frank A. Redegeld)]
Current Pharmaceutical Design Treatment with Melittin Induces Apoptosis and Autophagy of Fibroblast-like Synoviocytes in Patients with Rheumatoid Arthritis
Current Pharmaceutical Biotechnology A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
Current Pharmaceutical Design Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Subject Index to Volume 5
Current Pharmaceutical Biotechnology Complementary and Alternative Medical Therapies in Fibromyalgia
Current Pharmaceutical Design Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis
Current Vascular Pharmacology Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Current Drug Safety Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Validated UPLC-MS Method for Pharmacokinetic Investigations of Cyclosporine-A in Blood
Current Pharmaceutical Analysis Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Interleukin-26, An Epitheliotropic T-Cell Cytokine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot-Topic: Molecular Mechanisms in Rheumatic Diseases:Rationale for Novel Drug Development (Guest Editor: Charles J. Malemud)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Possibilities and Pitfalls for Anti-Complement Therapies in Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics